Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app and care partner help seniors with diabetes and memory loss?

NCT ID NCT05601583

Symptom relief Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This early-phase study looks at whether older adults (65+) with type 2 diabetes and mild cognitive impairment can better manage their blood sugar by sharing continuous glucose monitor data with a care partner via a mobile app. Fourteen participants and their care partners will use the system for two weeks, then give feedback through interviews. The goal is to see if this approach is acceptable and helpful for daily diabetes decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

14 people

The number who actually took part.

Started

Apr 2023

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Older adults must meet all of the following criteria: 1. be ≥ 65 years old; 2. have had a diagnosis of T2D for at least one year; 3. have MCI, defined as score 19-25 on the Montreal Cognitive Assessment (MoCA);60,61 4. have a care partner (e.g., spouse or adult children); 5. be willing to use CGM; 6. be fluent in English. Eligible care partners must be: 1. ≥ 18 years old; 2. living with older adults with T2D-MCI; 3. willing to be involved in patients' daily care; 4. fluent in English. Exclusion Criteria: Older adults who meet any of the following criteria will be excluded from participation in this study: 1. Refuse or are unable to provide informed consent; 2. Have serious physical illness (e.g., end-stage renal disease); 3. Presence of mental illness (e.g., schizophrenia or bipolar disorder) that would preclude participation. The care partners will be excluded if they: 1. Refuse or are unable to provide informed consent; 2. Have MCI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment Type 2 diabetes

Contacts and locations

Locations

  • Bellevue Hospital

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.